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Backgrounds/Aims: Aggressive surgical resection for hepatic metastasis is validated, however, concomitant liver and 
lung metastasis in colorectal cancer patients is equivocal. Methods: Clinicopathologic data from January 2008 through 
December 2012 were retrospectively reviewed in 234 patients with colorectal cancer with concomitant liver and lung 
metastasis. Clinicopathologic factors and survival data were analyzed. Results: Of the 234 patients, 129 (55.1%) had 
synchronous concomitant liver and lung metastasis from colorectal cancer and 36 (15.4%) had metachronous 
metastasis. Surgical resection was performed in 33 patients (25.6%) with synchronous and 6 (16.7%) with metachro-
nous metastasis. Surgical resection showed better overall survival in both groups (synchronous, p=0.001; metachro-
nous, p=0.028). In the synchronous metastatic group, complete resection of both liver and lung metastatic lesions 
had better survival outcomes than incomplete resection of two metastatic lesions (p=0.037). The primary site of color-
ectal cancer and complete resection were significant prognostic factors (p=0.06 and p=0.003, respectively). 
Conclusions: Surgical resection for hepatic and pulmonary metastasis in colorectal cancer can improve complete re-
mission and survival rate in resectable cases. Colorectal cancer with concomitant liver and lung metastasis is not a 
poor prognostic factor or a contraindication for surgical treatments, hence, an aggressive surgical approach may be 
recommended in well-selected resectable cases. (Korean J Hepatobiliary Pancreat Surg 2016;20:110-115)
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INTRODUCTION
The liver is the most frequent site of metastatic color-
ectal cancer, and metastatic lesions from colorectal cancer 
are frequently detected in the lungs, bones, and brain.1,2 
As surgical managements such as operative equipment in-
novation, operation strategy, and perioperative manage-
ment have advanced, morbidity and mortality associated 
with surgical resection are reduced to acceptable levels. 
Since the first report of liver or lung metastasectomy due 
to colorectal cancer,3 surgical resection of liver and lung 
metastatic lesions is considered the only therapeutic op-
tion for long-term survival.4 In addition, perioperative 
chemotherapy improves the resectability of meta-
stasectomy with minimal safety margins, which is an ac-
cepted standard procedure that is frequently performed 
worldwide.5 A safety resection margin of ＞1 cm, or a 
3-mm margin, is widely used for surgical resection of 
metastasis of colorectal cancer.6,7 Several clinical guide-
lines recommend surgical resection for synchronous or 
metachronous resectable metastatic lesions before or after 
systemic chemotherapy.2,8 However, the role of surgical 
resection in concomitant liver and lung metastasis is not 
clearly defined, and aggressive surgical resection may be 
a contributing factor in improvement of survival outcomes 
in patients with confirmed concomitant liver and lung 
metastasis.9 The aim of this study was to evaluate the effi-
cacy of surgical resection in concomitant synchronous or 
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Fig. 1. Selection of study 
patients. Flow chart describes the 
characteristics of patients in-
cluded in the analyses. CRC, 
colorectal cancer.
metachronous liver and lung metastasis from colorectal 
cancer.
MATERIALS AND METHODS
Patient selection
Data regarding patients with liver and lung metastasis 
from colorectal cancer from January 2008 to December 
2012 were reviewed retrospectively in our institutional 
cohort. Patients with concomitant liver and lung metastasis 
showing solitary or multiple lesions were then selected for 
the study, excluding non-surgical patients and patients with 
other metastasis besides liver and lung. Clinicopathologic 
and pathologic data was obtained and survival outcomes 
were analyzed in these patients (Fig. 1).
Surgical procedures
Liver and lung resections were performed by hep-
atobiliary surgeons and thoracic surgeons at a single 
institution. All surgical procedures were performed to 
completely remove the metastatic lesions in the liver or 
lung. Resections of the liver and lung were conducted for 
solitary or multiple lesions as one-step or two-step proce-
dure based on the surgeons’ discretion.
Follow-up and survival outcome
Patients who underwent surgical resection for liver or 
lung metastatic lesions were examined regularly after 
surgery. Physical examination, blood test, and compu-
terized tomography (CT) scan of the abdomen and thorax 
were performed at each evaluation. Patients were followed 
until the latest visiting days, including the date of death 
or loss to follow-up.
Statistics
Continuous variables were expressed as mean±standard 
deviation and categorical variables were expressed as fre-
quencies with percentages. The Mann-Whitney U test for 
continuous variables and the Chi-square test for catego-
rical variables were used to determine significant associa-
tions between parameters. The Kaplan-Meier method and 
log-rank test were used for survival analysis. Multivariate 
analysis using Cox-regression was done to identify sig-
nificant prognostic factors for overall survival. Statistical 
significance was determined if the p-value was ＜0.05.
RESULTS
Patient characteristics
The age of patients with synchronous metastasis was 
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Table 1. Clinicopathologic factors and detailed patterns of liver and lung metastasis in resected cases
Synchronous metastasis (n=33) Metachronous metastasis (n=6) p-value
Age (range, median)
Sex (Male/Female)
Preoperative CEA (ng/ml)
Primary CRC
  T stage (T1/T2/T3/T4)
  N stage (N0/N1/N2)
  Location
    Colon
    Rectum
Liver metastasis
  Number of lesions 
    (range, median)
    (solitary/multiple)
  Largest size (cm)
  Distribution
    Unilateral (Right/Left lobe)
    Bilateral
  Operation
    None
    Wedge resection
    Segmentectomy
    Lobectomy
    Extended lobectomy
    Intraoperative RFA
Lung metastasis
  Number of lesions 
    (range, median)
    (solitary/multiple)
  Largest size (cm)
  Distribution
    Unilateral (Right/Left lobe)
    Bilateral
  Operation
    None
    Wedge resection
    Lobectomy
  Adjuvant treatment
63 (29-78)
21 (63.6%)/12 (36.4%)
34.3 (3.4-85.4)
 
0/3/26/4
9/12/12
 
17 (51.5%)
16 (48.5%)
 
 
1-15 (7)
6 (18.2%)/27 (81.8%)
2.1 (0.8-4.5)
 
11 (33.3%)/7 (21.2%)
15 (45.5%)
 
2 (6.1%)
18 (54.4%)
 6 (18.2%)
3 (9.1%)
1 (3%)
3 (9.1%)
 
 
1-12 (5)
12 (36.4%)/27 (63.6%)
0.9 (0.5-3.1)
 
9 (27.3%)/7 (21.2%)
17 (51.5%)
 
13 (39.4%)
18 (54.5%)
2 (6.1%)
13 (39.4%)
 46 (35-58)
2 (33.3%)/4 (66.6%)
 12.8 (2.5-56.3)
 
0/0/6/0
1/4/1
 
  2 (33.3%)
  4 (66.7%)
 
 
1-3 (1)
4 (66.7%)/2 (33.3%)
 2.4 (1.0-3.4)
 
4 (66.6%)/2 (33.3%)
0
 
  1 (16.7%)
  2 (33.3%)
  2 (33.3%)
  1 (16.7%)
0
0
 
 
1-2 (1)
5 (83.3%)/1 (16.7%)
1.0 (0.6-2.8)
 
2 (33.3%)/4 (66.6%)
0 (0%)
 
0 (0%)
  6 (100%)
0 (0%)
  2 (33.3%)
0.01
0.03
0.01
 
0.686
0.147
 
0.124
 
 
 
0.001
 
0.684
 
0.003
 
 
0.576
 
 
 
 
 
 
 
0.001
 
0.849
 
0.002
 
 
0.492
 
 
0.824
SD, standard deviation; CEA, carcinoembryonic antigen; CRC, colorectal cancer; RFA, radiofrequency ablation
significantly higher than that of patients with metachro-
nous metastasis, and female patients were frequently iden-
tified with metachronous metastasis. T stage, N stage, and 
location of primary colorectal cancer was not significantly 
different between synchronous and metachronous meta-
stasis patients (Table 1).
Detailed pattern of metastasis
There were more liver lesions in synchronous than 
metachronous metastasis, without significant difference in 
largest size of solitary or multiple metastatic lesions be-
tween the two groups. In addition, synchronous metastasis 
showed multiple metastatic lesions in both liver lobes 
compared to metachronous metastasis, and the surgical 
method was not remarkably different between the two 
groups.
Multiple metastatic lesions of lung in the synchronous 
metastases were more frequent than in the metachronous 
metastasis, though size of lung metastases were not sig-
nificantly different for either groups. Bilateral lung meta-
stasis was more frequent in synchronous metastasis com-
pared to metachronous metastasis, and the surgical meth-
od was not statistically different between both groups 
(Table 1).
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Table 2. Clinical course and recurrence pattern of resected cases
Synchronous metastasis 
(n=33)
Metachronous metastasis 
(n=6) p-value
Follow-up period (median, range, month)
Adjuvant treatment
Resection pattern
  Complete resection (Simultaneous/Staged)
  Incomplete resection
Postoperative CEA (POD 1 month, ng/ml)
Postoperative mortality
Recurrence rate
Recurrence interval (months, range)
Recurred site
  Liver
  Lung
  Liver+Lung
  Carcinomatosis
  Other (Bone, brain, etc.)
     22 (1-78)
     13 (39.4%)
 
9 (27.3%)/9 (27.3%)
     15 (45.5%)
    3.2 (1.9-12.4)
      0 (0%)
     21 (63.6%)
     18 (3-79)
 
      4 (12.1%)
      3 (9.1%)
      8 (24.2%)
      3 (9.1%)
      3 (9.1%)
   21 (2-38)
    2 (33.3%)
 
3 (50%)/2 (33.3%)
    1 (16.7%)
   1.3 (1.2-7.2)
    0 (0%)
    5 (83.3%)
   22 (10-68)
 
    2 (33.3%)
    0 (0%)
    0 (0%)
    1 (16.7%)
    2 (33.3%)
0.547
0.824
0.04
 
 
0.01
ns
0.15
0.652
0.754
 
 
 
 
 
CEA, carcinoembryonic antigen; POD, postoperative day
Clinical and oncologic outcomes
The median follow-up periods for synchronous and 
metachronous metastasis were 22.2 and 21.6 months, re-
spectively, from the time of the operation. Preoperative 
adjuvant treatments were performed for 39.4% and 33.3% 
of patients in synchronous and metachronous groups, 
respectively. Complete surgical resections confirmed by 
postoperative imaging study were conducted for 54.6% 
and 83.3% of patients in each group. Unresected meta-
static lesions in liver were treated by radiofrequency abla-
tion (RFA) (Table 1).
There was no postoperative mortality within 30 days af-
ter operation (Table 2). Recurrence after surgical resection 
was 63.6% and 83.3% in the synchronous and metachro-
nous groups, respectively. Survival analysis was per-
formed using the Kaplan-Meier method and log-rank test. 
In the synchronous metastasis group, the resection group 
had statistically better survival, as compared to the non-re-
section group (p＜0.001). Furthermore, complete resection 
of both liver and lung metastasis had significantly better 
survival than the incomplete resection group (p=0.037). 
Additionally, in the metachronous group, the resection 
group had significantly better survival, as compared to the 
non-resection group (p=0.028) (Fig. 2).
Prognostic factors
Multivariate analysis for prognostic factors of overall 
survival was performed using previously known prog-
nostic factors and potential clinical markers. Rectal pri-
mary cancer was marginally significant (p=0.06, hazard 
ratio (HR)=0.988-2.318), and incomplete surgical re-
section for metastatic lesions was most significant 
(p=0.003, HR=1.477-6.441) for predicting poor outcomes 
in concomitant liver and lung metastasis from colorectal 
cancer (Table 3).
DISCUSSION
Colorectal cancer leads to metastatic disease in 60% of 
cases, with frequent involvement of the liver, lungs, or 
both.5 Following several reports of promising results after 
surgical resection of liver metastasis from colorectal can-
cer, the paradigm has shifted from limited indication for 
hepatic resection to an active surgical approach.1,4 
Currently, the only absolute contraindication is the inabil-
ity to obtain a tumor-free margin and maintain adequate 
liver function. Surgical resection is the only way to ach-
ieve long-term survival in patients with colorectal cancer 
liver metastases;10 and several comparative studies have 
revealed that surgical resection shows better survival out-
comes, as compared to systemic chemotherapy alone.11-13
Although several studies have explored optimal treat-
ment strategies, there are still limitations for specific 
guidelines in a patient with synchronous or metachronous 
concomitant liver and lung metastasis from colorectal 
cancer.9,10 Treatment strategy differs between institutions 
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Fig. 2. Survival analysis for synchronous and metachronous 
metastasis from colorectal cancer. Survival analysis using the 
Kaplan-Meier method and log-rank test (A) in the synchro-
nous metastasis group, the resection group showed sig-
nificantly better survival compared to the non-resection 
group. (B) Complete resection for both liver and lung meta-
stasis had significantly better survival compared to the in-
complete resection group. (C) In the metachronous group, the 
resection group showed significantly better survival com-
pared to the non-resection group.
Table 3. Multivariate analysis for prognostic factors of overall survival
Cox proportional hazard analysis p-value HR 95% Confidential interval
Age (＞60 yrs)
Sex (Male/Female)
Pattern of metastasis (Metachronous/Synchronous)
T stage of CRC (T3,4/T1,2)
N stage of CRC (Positive/Negative)
Bilateral distribution (Bilateral/Unilateral)
Surgical resection (Complete/Incomplete)
Primary location of CRC (Rectum/Colon)
Preoperative CEA
0.646
0.664
0.665
0.116
0.113
0.735
0.003
0.06
0.09
1.156
1.092
0.819
1.386
1.531
0.769
3.084
1.475
2.481
0.623
0.733
0.331
0.922
0.904
0.231
1.477
0.988
0.842
2.144
1.626
2.026
2.083
2.593
2.452
6.441
2.318
12.458
HR, hazard ratio; CRC, colorectal cancer; CEA, carcinoembryonic antigen
due to differing clinical situations of patients and the in-
stitute’s management plan. Nevertheless, several studies 
emphasize the importance of complete surgical resection 
in patients with concomitant liver and lung metastasis 
with colorectal cancer.14-16 In this study, the pattern of 
clinicopathologic factors, particularly the preoperative and 
postoperative levels of carcinoembryonic antigen (CEA), 
were evaluated for synchronous or metachronous meta-
stasis from primary colorectal cancer. Although several 
clinical features differed based on the timing of metastasis 
from primary colorectal cancer, only complete resection 
of the metastatic liver and lung lesions improved survival 
outcomes.
The prognostic factors for liver and lung metastasis 
from colorectal cancer in terms of CEA, rectal primary 
cancer, bilateral lung metastasis, and multiple metastases 
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have been recently reported.14,17,18 In particular, complete 
surgical resection of both liver and lung metastasis is the 
most significant prognostic factor for patients with con-
comitant liver and lung metastasis with colorectal cancer, 
according to a study on the synchronism of liver and lung 
metastasis.9 The resectability of liver and lung metastasis 
has gradually increased due to the progress in surgical 
skill and technique, and improvement of perioperative 
management. Recent advances in molecular biology have 
also offered new prognostic factors, e.g., KRAS, BRAF, 
NRAS, and PIK3CA mutations, for patients with meta-
static colorectal cancer in the era of precision medicine.19
This study has several limitations in terms of retro-
spective design, single-center study, and small study 
population. The heterogeneous clinical status of the en-
rolled population is another limitation. However, the evi-
dence regarding the clinical situation for concurrent liver 
and lung metastasis in colorectal cancer is relatively rare 
and the strategy for this situation is not yet established. 
Therefore, this study increases our current understanding 
of concurrent liver and lung metastasis in colorectal 
cancer.
In conclusion, the results of this study indicated that the 
resection of hepatic and pulmonary metastases from color-
ectal cancer is safe and can offer long-term survival to se-
lected patients. Surgery should be considered only if re-
section of all metastatic sites are potentially curative. 
Furthermore, resections should be as limited as possible to 
allow for repeat resections for eventual disease recurrence.
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